When Novo Nordisk’s semaglutide patent expired in India in March 2026, the country’s pharmaceutical industry moved at lightning speed. Within just 48 hours, more than sixteen generic versions of Ozempic hit the market, slashing prices by up to 90%. This moment captured India’s strength—its unmatched ability to copy and scale any drug faster than anywhere else.
Yet, beneath the triumph lies a sobering truth: despite scale, India has yet to deliver a globally successful first-in-class drug. Generics remain profitable but lack the prestige, royalties, and durable pricing of originator medicines.
Some companies are beginning to push the boundaries:
- Zydus advancing obesity drug programs like Saroglitazar and Utreglutide.
- Mankind Pharma developing MKP10241, a pill-based obesity treatment candidate.
- Sun Pharma exploring Utreglutide, a distinct GLP-1 agonist with lipid-lowering potential.
But the road to innovation is steep—high R&D costs ($1–2B, 10–15 years), fragmented discovery efforts, and limited alignment with USFDA standards. China’s example shows what’s possible: heavy investment in R&D and regulatory reform has already led to original drugs approved globally. India risks being left behind if it remains focused only on generics.
🔬 Anveta Therapeutics’ Perspective
Anveta Therapeutics, headquartered in Bengaluru and Mumbai, is strategically aligned with this challenge.
- Mission: Translate innovative academic science into differentiated small-molecule therapeutics.
- Model: Co-development approach where originating researchers remain engaged through discovery, IND-enabling studies, and early clinical development.
- Strengths:
- Team has experience in development drugs across multiple therapeutic areas.
- Integrated tech platform for data-driven discovery and trial management.
- Global collaborations with academic and institutional partners.
- Focus Areas: Early-stage discovery, first-in-class or best-in-class differentiation, and clinical proof-of-concept studies.
🌍 Why This Matters
India’s generics dominance is unsustainable for long-term growth; margins collapse quickly after patent expiry. By bridging academia and industry, Anveta is building the “valley of death” infrastructure—moving promising compounds from lab research to IND-ready packages. With disciplined discovery and early clinical impact, Anveta could help India replicate China’s success in shifting from generics to innovation.
Strategic Fit: Anveta is positioned as a drug discovery incubator that complements large pharma’s scale with nimble, innovation-driven pipelines—helping India evolve from a generics powerhouse into a true drug discovery leader.